Clinical Trial Update: Single-Ascending Dose Study of AMG 333 in Healthy Subjects and Subjects With Migraines [Phase 1]

View source ↗

Summary

A Phase 1 single-ascending-dose study of AMG 333 in healthy subjects and patients with migraine has completed, reporting early safety and pharmacokinetic data.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Migraine

Drugs mentioned

• AMG 333

Snippet

Sponsor: Amgen | Conditions: Migraine | Phase 1 | Status: COMPLETED